(2R)-2-[(1R)-1-{[(2S)-2-Carboxy-2-(4-hydroxyphenyl)acetyl]amino}-1-methoxy-2-oxoethyl]-5-methylene-5,6-dihydro-2H-1,3-oxazine-4-carboxylic acid
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- (2R)-2-[(1R)-1-{[(2S)-2-Carboxy-2-(4-hydroxyphenyl)acetyl]amino}-1-methoxy-2-oxoethyl]-5-methylene-5,6-dihydro-2H-1,3-oxazine-4-carboxylic acid
- DrugBank Accession Number
- DB02588
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for (2R)-2-[(1R)-1-{[(2S)-2-Carboxy-2-(4-hydroxyphenyl)acetyl]amino}-1-methoxy-2-oxoethyl]-5-methylene-5,6-dihydro-2H-1,3-oxazine-4-carboxylic acid (DB02588)
- Weight
- Average: 406.3435
Monoisotopic: 406.101230184 - Chemical Formula
- C18H18N2O9
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UBeta-lactamase Not Available Escherichia coli (strain K12) - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
- InChI Key
- GOYCBKVVHGALFQ-RZAIGCCYSA-N
- InChI
- InChI=1S/C18H18N2O9/c1-9-7-29-17(19-13(9)16(26)27)18(8-21,28-2)20-14(23)12(15(24)25)10-3-5-11(22)6-4-10/h3-6,8,12,17,22H,1,7H2,2H3,(H,20,23)(H,24,25)(H,26,27)/t12-,17+,18-/m0/s1
- IUPAC Name
- (2R)-2-{1-[(2S)-2-carboxy-2-(4-hydroxyphenyl)acetamido]-1-methoxy-2-oxoethyl}-5-methylidene-5,6-dihydro-2H-1,3-oxazine-4-carboxylic acid
- SMILES
- COC(NC(=O)[C@@H](C(O)=O)C1=CC=C(O)C=C1)(C=O)[C@H]1OCC(=C)C(=N1)C(O)=O
References
- General References
- Not Available
- External Links
- PubChem Compound
- 131704211
- PubChem Substance
- 46506599
- ChemSpider
- 26328061
- ZINC
- ZINC000015529397
- PDBe Ligand
- MOX
- PDB Entries
- 1fco / 1i5q
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.225 mg/mL ALOGPS logP 1.11 ALOGPS logP 1.4 Chemaxon logS -3.3 ALOGPS pKa (Strongest Acidic) 2.9 Chemaxon pKa (Strongest Basic) -3.7 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 10 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 171.82 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 94.83 m3·mol-1 Chemaxon Polarizability 37.01 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.8196 Blood Brain Barrier - 1.0 Caco-2 permeable - 0.6744 P-glycoprotein substrate Substrate 0.8161 P-glycoprotein inhibitor I Non-inhibitor 0.6713 P-glycoprotein inhibitor II Non-inhibitor 0.6452 Renal organic cation transporter Non-inhibitor 0.9366 CYP450 2C9 substrate Non-substrate 0.8483 CYP450 2D6 substrate Non-substrate 0.8706 CYP450 3A4 substrate Substrate 0.6358 CYP450 1A2 substrate Non-inhibitor 0.807 CYP450 2C9 inhibitor Non-inhibitor 0.8242 CYP450 2D6 inhibitor Non-inhibitor 0.8963 CYP450 2C19 inhibitor Non-inhibitor 0.7774 CYP450 3A4 inhibitor Non-inhibitor 0.7485 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7646 Ames test Non AMES toxic 0.5666 Carcinogenicity Non-carcinogens 0.9284 Biodegradation Not ready biodegradable 0.9854 Rat acute toxicity 2.3783 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9962 hERG inhibition (predictor II) Non-inhibitor 0.8606
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-000i-0209100000-e4c975297808c4b47cb3 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4i-1319800000-d1c7fbc979e77ad6f27e Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-000i-0912000000-e7a7bf177b30739d7079 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-005l-1916000000-d37727459309114266fb Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-053r-0903000000-afb0a9abd5c3adf6c56c Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4m-4900000000-49d1491db1b6586bc324 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 184.15738 predictedDeepCCS 1.0 (2019) [M+H]+ 186.26129 predictedDeepCCS 1.0 (2019) [M+Na]+ 192.17427 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Unknown
- General Function
- Beta-lactamase activity
- Specific Function
- This protein is a serine beta-lactamase with a substrate specificity for cephalosporins.
- Gene Name
- ampC
- Uniprot ID
- P00811
- Uniprot Name
- Beta-lactamase
- Molecular Weight
- 41555.3 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Drug created at June 13, 2005 13:24 / Updated at August 01, 2020 13:44